Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Drug: Rituximab, CMC544, Gemcitabine and Oxaliplatine
- Registration Number
- NCT01562990
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Brief Summary
The purpose of this study is to determine the recommended dose of CMC544 administered in combination with rituximab (R-CMC544), and in alternance with rituximab, gemcitabine and oxaliplatin (R-GEMOX) in the first phase of the study. After that, efficacy and safety of this combination will be evaluated preliminarily in patients with DLBCL in relapse or refractory, who are no candidates for autologous transplant.
- Detailed Description
This study is a multicenter, phase Ib/II, open-label, single arm trial evaluating the efficacy and safety of R-CMC544 alternated with R-GEMOX in patients with CD20 and CD22 positive DLBCL in relapse after/refractory to 1st or 2nd line treatment, who are no candidates for autologous transplant.
The study consists of 2 phases. In part 1 (potential dose de-escalation phase) subjects will be enrolled at a fixed dose of CMC544. In case of occurrence of dose limiting toxicity (DLT), cohorts of 3 to 6 subjects will evaluate a de-escalating dose of CMC544 in combination with set doses of rituximab, gemcitabine and oxaliplatin in order to obtain the MTD or recommended dose of CMC544 in this regimen. In part 2 (dose expansion phase) further safety and preliminary efficacy data of the proposed combination will be analyzed.
All patients will receive two 56 day induction cycles of alternating R-CMC544 (given on day 1) and R-GEMOX (given on day 29 and 43). Patients who obtain CR or PR, will then go on a consolidation of another two 56 day cycles of alternating R-CMC544 (given on day 1) and R-GEMOX (given on day 29 and 43).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
- Histologically documented CD20 and CD22 positive diffuse large B-cell lymphoma, according to WHO classification. CD20 and CD22 immunophenotyping at initial diagnosis is acceptable. If such prior documentation is not available, then the immunophenotyping at relapse must be established by fine-needle aspirate or biopsy or by circulating CD20 and CD22 positive NHL cells from peripheral blood during screening. Upon registration the pathological report confirming the diagnosis, must be available
- In first or second relapse or refractory to first and/or second line treatment. Refractory is defined as having exhibited less than or PR to a prior rituximab containing regimen or having relapsed within 6 months of the last dose of a prior rituximab containing regimen.
- Measurable disease by bidimensional transverse CT scan assessment
- Not eligible for autologous transplantation.
- Previously treated with a chemotherapy regimen containing anthracyclines and rituximab.
- Aged 18 - 80 years.
- ECOG performance status 0 to 2.
- Minimum life expectancy of 3 months.
- Signed written informed consent.
- Burkitt, mantle cell and T-cell lymphomas.
- Central nervous system or meningeal involvement by the lymphoma.
- Contraindication to any drug contained in the R-GEMOX combination chemotherapy.
- Treatment with any investigational drug within 30 days before the first planned cycle of chemotherapy and during the study.
- Nitrosurea or mitomycin C administration within 6 weeks prior to study start.
- Major debulking surgery within 3 weeks of treatment.
- Any of the following lab abnormalities (unless related to the lymphoma or bone marrow infiltration):
Absolute neutrophil count (ANC) < 1.500/µL (1,5.109/L).
Platelet count < 100.000/µL (100.109/L).
Creatinin level > 150 µmol/L (1,7 mg/dL) or 1,5 - 2,0x ULN.
Total bilirubin level > 30 µmol/L (1,8 mg/dL) or 1,5x ULN.
Serum AST/SGOT or ALT/SGPT >2,5x ULN.
- Documented infection with HIV, active hepatitis B or C infection.
- Any serious active disease or co-morbid medical condition that, according to the investigator's decision, will substantially increase the risk associated with the subject's participation in the study. Prior history of malignancies other than lymphoma with the exception of non-melanoma skin tumors (basal cell or squamous cell carcinoma of the skin) or stage 0 (in situ) cervical carcinoma unless the subject has been disease-free for 5 or more years..
- LVEF less than 50% (measured by echocardiography or scintigraphy).
- Previous myocardial infarction or pulmonary hypertension within 6 months before the first dose of investigational product.
- Congestive heart failure NYHA stage III or IV
- Known chronic liver disease (eg. Cirrhosis) or suspected alcohol abuse.
- Pregnant or lactating females
- Men and women who are biologically capable of having children not willing to use an adequate method of birth control during the study and up to 18 months after the last dose of investigational product.
- Adult patient unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description R-CMC544 and R-GEMOX Rituximab, CMC544, Gemcitabine and Oxaliplatine Treatment with R-CMC544 and R-GEMOX
- Primary Outcome Measures
Name Time Method Determination of the Recommended Dose of R-CMC544 Up to 16 weeks Determination of recommended dose will be based on safety parameters and particularly on incidence of DLTs
- Secondary Outcome Measures
Name Time Method PROGRESSION-FREE SURVIVAL Up to 3.5 years Progression-Free Survival will be measured from the date of inclusion to the date of first documented disease progression, relapse or death from any cause. Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date.
OVERALL SURVIVAL Up to 3.5 years Overall survival will be measured from the date of inclusion to the date of death from any cause. Patients who are alive at the time of analysis will be censored at the date of the last contact.
COMPLETE RESPONSE RATE 30 or 32 weeks (depending on induction cycle length) Assessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 2007)).
Patient without response assessment (due to whatever reason) will be considered as nonresponder.OVERALL RESPONSE RATE Up to 32 weeks Assessment of response will be based on the International Workshop to Standardize Response criteria for NHL (Criteria for evaluation of response in Non-Hodgkin's lymphoma (Cheson, 1999 and 2007). Patient is defined as a responder if he/she has a complete response (CR) or partial response (PR) at the end of treatment. A descriptive analysis will also be performed considering as non-responders all patients who relapsed or died during treatment phase even if they were prematurely withdrawn as responder
EVENT FREE SURVIVAL Up to 3.5 years Event-Free Survival will be measured from the date of inclusion to the date of first documented disease progression, relapse, initiation of new anti-lymphoma therapy or death from any cause. Responding patients and patients who are lost to follow up will be censored at their last tumor assessment date.
Trial Locations
- Locations (11)
CHU de Dijon
🇫🇷Dijon, France
AZ Sint Jan
🇧🇪Bruges, Belgium
CHRU de Lille
🇫🇷Lille, France
CHU Hôtel Dieu
🇫🇷Nantes, France
CHU Lyon - Sud
🇫🇷Lyon, France
CHU Pontchaillou
🇫🇷Rennes, France
CHU Brabois
🇫🇷Vandoeuvre les nancy, France
Hôpital Henri Mondor
🇫🇷Créteil, France
Centre Henri Becquerel
🇫🇷Rouen, France
University Hospital Gent
🇧🇪Gent, Belgium
CHU Mont-Godinne
🇧🇪Yvoir, Belgium